Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF.
In 4 out of 16 patients receiving recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) in phase I/II studies antibodies developed to the recombinant protein. The antibodies react with sites on the native protein backbone which are normally protected by O-linked glycosylation but which are exposed in rhGM-CSF produced in yeast and Escherichia coli. Antigenicity of recombinant human proteins due to non glycosylation may have relevance to the choice of host system for production of factors for clinical use.
Version: za2963e q8za4 q8zb2 q8zcf q8zd7 q8zef q8zfd q8zg3